Immunochina Pharmaceuticals nabs about $20.4 mln

Beijing-based Immunochina Pharmaceuticals, a provider of cancer diagnosis and treatment services, has raised about $20.4 million in funding. The investors included Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital and China Resources Innovative Equity Investment Fund.